Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
about
Interleukin-6: an emerging regulator of pathological painThe Role of the Transcriptional Regulation of Stromal Cells in Chronic InflammationPerformance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk predictionConstructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.Impact of CD44 expression on radiation response for bladder cancerKPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cellsKnockout of the Nogo-B Gene Attenuates Tumor Growth and Metastasis in Hepatocellular Carcinoma.Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells.Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppressionThe role of interleukin-6 in malignant mesotheliomaFibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment.SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.Soluble interleukin-6 receptor to interleukin-6 (sIL‑6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomyInterleukin-6 as a potential molecular target in esophageal squamous cell carcinoma.Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulationRole of maspin in cancer.Significance of Interleukin-6 in Papillary Thyroid Carcinoma.IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagusMechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells.The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.Cancer prevention and therapy through the modulation of the tumor microenvironment.A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathwayInterleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction.Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress responseInterleukin-6: a multifunctional targetable cytokine in human prostate cancer.Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.Emerging biomarkers of prostate cancer (Review)Androgen receptor signaling in prostate cancer.Proinflammatory cytokine interleukin-6 in prostate carcinogenesisThe role of microRNA-26a in human cancer progression and clinical application.Correlation and malignant transformation of MSCs with the overexpression of SIL-R/GP130 under the tumor microenvironment.Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
P2860
Q26748646-86C48B12-3F3A-4E29-9CC4-8DB5DC02BF0EQ26778930-2E2B3A14-9C3F-4AB1-90E1-2C7558DAA58AQ28727717-2C98F283-DDFC-4925-B60A-34DF656D1364Q31130674-F4B73A91-61F8-4C5B-85DB-47331DF86618Q33776678-FE5D3BA0-079F-43BD-B71B-DF7791581EADQ33779276-7BC6EC93-631F-4892-BDC7-ADF898241227Q33813952-EB8AAB28-820A-47E4-A939-50405FABEE91Q34094656-D085F1F2-5596-4C63-A9E3-3E3301C95D9BQ34362985-B8791E82-B851-417C-A323-BA1FC706B158Q34484057-2ECC7A8E-E4B4-4082-8485-DE342CDACA75Q35003674-F0541D46-B08D-4CA6-95DF-B71BAE214F66Q35037290-5C7AB99F-BC7A-4360-A5B7-70DF87244E5FQ35097484-0C940AE0-E1B8-4071-AE8B-1C06AE8FE5B2Q35200628-BB116B5E-F680-4898-9973-3FF42CA330E0Q35666458-7723679C-2F91-4B73-BA6A-C5A20F2AADBBQ35983468-C9DB0EFB-C0D1-4B79-9A92-D1E8B80BA5DBQ36126540-4D02702B-47FA-4882-BA74-860A08B77F32Q36524059-1CEC6B31-1DCE-4612-BB58-B72A597B3C76Q36562147-D578D8ED-16D8-4C5A-9B6B-35C9EB8B6204Q36698729-6822D911-45C2-4BEB-BB2C-7E4DF5826039Q36731164-CC03AC2F-44B8-44FA-8C79-B74308D2D0ACQ36885478-D579CA2F-A292-4987-BE86-00F2EB247BC8Q36898645-FA4C5BDF-CE9D-452F-933A-37E2FD4643DFQ36946662-BE230573-1D25-47CA-BBA8-D17E32B52997Q37058267-309DA5BF-1898-4250-A741-48204AB485F8Q37189154-770E97F6-A13C-4F7E-9E29-77CEE510C6B3Q37507447-D6BF0A18-9AD3-44B7-AA37-87AF0BF281E9Q37688291-8BA8A46A-010F-4719-B541-DD5D01741CBFQ37888027-A998DDBD-B4E2-447F-9E1C-9A5D87EBE60CQ37947091-BA851DCC-E180-4515-BD25-00B59EBF9309Q37968599-FE69C6A2-AC69-4437-BDEA-B25F0A26BDC0Q38013967-F6BE688C-8021-4528-980E-6F0021CC6D29Q38175320-2BFC532F-B2B8-4414-9167-9EE005F08845Q38265575-4B42E686-A074-42AE-93AA-D01F92856CD0Q38796729-E02C48DC-174B-4DC7-8559-368D3E92C1F9Q38936973-FF1E7581-1FE1-426A-B53A-D16130201E17Q39024619-2BD3155D-33E8-4F39-A6C2-08BEF3D49804Q39224207-CA5B551E-4458-4A0B-B905-8107ED648FF3Q39236369-87D22B08-7AEC-417E-BA3E-D86BE94EA4EFQ39265565-7D53DFAA-8F46-4D18-AB28-100D90B921D2
P2860
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@ast
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@en
type
label
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@ast
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@en
prefLabel
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@ast
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@en
P2093
P2860
P356
P1476
Interleukin-6 trans-signalling ...... in human prostate cancer cells
@en
P2093
Frédéric R Santer
Ilaria T Cavarretta
Kamilla Malinowska
Zoran Culig
P2860
P304
P356
10.1677/ERC-09-0200
P577
2010-02-18T00:00:00Z